Minor Tweak, Major Impact cover art

Minor Tweak, Major Impact

Minor Tweak, Major Impact

By: Minor Tweak Major Impact
Listen for free

About this listen

 A short-form science podcast Science
Episodes
  • Minor Tweak, Major Impact Podcast Introduction

    Minor Tweak, Major Impact Podcast Introduction
    Mar 13 2019
    Minor Tweak, Major Impact is a short form podcast about scientific research methods. The show looks into a series of stories related to following protocols and how a minor tweak can produce major results, major impact.
    Show More Show Less
    Less than 1 minute
  • Episode 01: Luke Schwerdtfeger, Colorado State University

    Episode 01: Luke Schwerdtfeger, Colorado State University
    Mar 13 2019
    Luke Schwerdtfeger graduated from Colorado State University with a Bachelor's Degree in Biological Sciences, prior to joining the same universities PhD program in the Department of Biomedical Sciences. Luke’s doctoral work, for which he is advised by Dr. Stuart Tobet, focuses on understanding the nervous system of the mammalian intestine and how it functions in response to pathogen invasion.
    Show More Show Less
    12 mins
  • Episode 02: Dr. Glenn Begley, CEO of BioCurate

    Episode 02: Dr. Glenn Begley, CEO of BioCurate
    Mar 25 2019
    Dr. Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities and created to provide commercial focus in the early phases of drug development. He served as Chief Scientific Officer at Akriveia Therapeutics, California (2016-2017) and TetraLogic Pharmaceuticals, Pennsylvania (2012-2016). From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen’s 5 research sites. There he highlighted the issue of research integrity and scientific reproducibility. Since then he has made multiple presentations on the subject of scientific integrity including to President Obama's Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, the British Broadcasting Company, Australian National Health and Medical Research Council, and numerous Universities, Research Institutes and companies. Before Amgen he had over 20 years of clinical experience in medical oncology and hematology. His personal research focused on regulation of hematopoietic cells and translational clinical trials. His early studies, in Prof Donald Metcalf’s department first described human G-CSF, and in later clinical studies, performed in Professor Richard Fox’s Department at the Royal Melbourne Hospital, the group first demonstrated that G-CSF-"mobilized" blood stem cells hastened hematopoietic recovery, a finding that revolutionized bone-marrow transplantation. His honors include being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, to the Association of American Physicians in 2008, and in 2014 to the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital and to the Australian Academy of Health and Medical Sciences.
    Show More Show Less
    18 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.